Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence [Internet]

The treatment of chronic hepatitis C (CHC) using the all oral, interferon-free regimen has potential advantages compared with interferon-based regimens. This report reviews the evidence of clinical effectiveness and safety of Harvoni and Holkira Pak for the management of CHC genotype 1, which may assist in healthcare funding decision-making in the context of the publicly funded healthcare system. Due to the complex generic names, the trade names of these therapies will be used in the review for clarity.